FDA approval of KRESLADI may grant Priority Review Voucher.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approval of KRESLADI may grant Priority Review Voucher.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The administration has signed an executive order and issued priority vouchers to accelerate the drug approval process through the FDA.
- Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA granted Priority Review for the BLA submission of the SkinTE product.
Coverage
Newest first; wire copies grouped- Insider MonkeyRocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the most promising penny stocks under $5. On July